DelveInsight’s Wet Age-related Macular Degeneration market report provides an in-depth understanding of Wet Age-related Macular Degeneration, historical and forecasted epidemiology, and market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). The report also discusses current Wet-AMD symptom treatment practices and algorithms, market drivers, market barriers, and unmet medical needs.
Some of the Key Highlights from the Wet Age-related Macular Degeneration Market Report
As per DelveInsight’s Wet Age-related Macular Degeneration epidemiology insights, the total diagnosed prevalent population was estimated to be 4,426,968 in the 7MM in 2020.
Among the EU5 countries, Germany had the highest Wet AMD prevalent population while Spain had the least in 2020.
As per the estimates, the highest number of WET AMD cases were reported in the age group of 61-70 years in the US in 2020.
Some of the leading players in the global Wet AMD market in the late phase of clinical development include Roche, Kodiak Sciences, REGENXBIO, Chengdu Kanghong Biotech, Opthea, among others.
Key Wet AMD pipeline therapies that are soon to be available in the market include Faricimab, Conbercept, KSI-301, OPT-302, RGX-314, and others.
KSI-301 is a novel anti-VEGF biologic that is designed to inhibit VEGF quickly while also providing an extended duration of action to reduce the burden of frequent anti-VEGF injections. It is being developed and investigated in phase III studies by Kodiak Sciences.
Faricimab (RG7716), developed by Roche, is the first bispecific antibody developed using CrossMab technology, is specifically designed for intravitreal use to bind to and neutralize both angiopoietin-2 (Ang-2) and VEGF-A with high potency and specificity.
For more insights into the disease, request for the sample @ Difference between Wet and Dry AMD
The Wet AMD market report also covers current treatment practices, emerging drugs, and their market share of individual therapies, as well as current and forecasted Wet-AMD symptoms market size from 2017 to 2030, segmented by seven major markets.
Wet Age-related Macular Degeneration: Overview
Wet Age-related Macular Degeneration is a type of age-related macular degeneration characterized by sudden central vision loss caused by abnormal blood vessels that bleed or leak fluid, causing the macula to swell and damage. It is also known as neovascular AMD and accounts for approximately 10% of AMD cases but nearly 90% of AMD-related central vision loss. Although non-neovascular or atrophic AMD accounts for 80% of patients, neovascular AMD accounts for nearly 90% of the severe, central visual acuity loss associated with AMD.
Wet Age-related Macular Degeneration Epidemiology Segmentation
The Wet Age-related Macular Degeneration report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
Wet Age-related Macular Degeneration Total Prevalent Cases
Wet Age-related Macular Degeneration Gender-Specific Cases
Wet Age-related Macular Degeneration Age-Specific Cases
Wet Age-related Macular Degeneration Treatment Landscape
Wet AMD has no cure, but an appropriate treatment could delay disease progression, avoiding the negative impact of vision loss on these patients’ quality of life. The current Wet AMD treatment options include Angiogenesis inhibitors (Lucentis, Eylea, Macugen, and Boevu), Photodynamic therapy (PDT), Laser photocoagulation surgery, antioxidant vitamins, and other nutrients. Some off-label drugs such as Avastin are also used as a treatment for Wet AMD.
Wet Age-related Macular Degeneration Market
The Wet AMD market size was found to be USD 7,459 million in the 7MM in 2020.
Among the 7MM, the US accounted for 31.1% of the overall Wet AMD market size in 2020.
Among EU5 countries, Germany accounted for the highest Wet AMD market share while Spain captured the least Wet AMD market size in 2020.
The Wet AMD market size is anticipated to increase owing to the launch of emerging therapies such as Faricimab, Conbercept, and others during the study period (2018-2030).
Wet Age-related Macular Degeneration Pipeline Therapies and Key Companies
Faricimab: Roche
Conbercept: Chengdu Kanghong Biotech
KSI-301: Kodiak Sciences
OPT-302: Opthea
RGX-314: Regenxbio
Learn more about the emerging drugs and companies @ Wet AMD Treatment Breakthroughs
Wet Age-related Macular Degeneration Market Drivers
Drugs in Pipeline
Personalized treatment
Increased WET AMD Prevalence
Genetic Therapy
Wet Age-related Macular Degeneration Market Barriers
Cost of Therapy
Launch of Biosimilars
Future competition among similar drugs
Scope of the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)
Study Period: 2018-30
Wet AMD Key Companies: Roche, Kodiak Sciences, REGENXBIO, Chengdu Kanghong Biotech, Opthea, among others.
Wet AMD Key Pipeline Therapies: Faricimab, Conbercept, KSI-301, OPT-302, RGX-314, and others.
Wet AMD Segmentation: By Geography, Wet AMD drugs
Analysis: Comparative and conjoint analysis of Wet AMD emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
1.
Key Insights
2.
Executive summary
3.
Organizations
4.
Wet Age-related Macular Degeneration (wet AMD): Market Share Overview at a Glance
5.
Wet Age-related Macular Degeneration (wet AMD): Market Overview at a Glance
6.
Wet AMD Epidemiology and Patient Population
7.
Treatment of Wet Form Age-related Macular Degeneration (wet AMD)
8.
Wet AMD Unmet Needs
9.
Wet AMD Marketed drugs
10.
Wet AMD Emerging Therapies
11.
Other Wet AMD Promising Therapies
12.
Wet Age-related Macular Degeneration (wet AMD): Seven Major Market Analysis
13.
Wet AMD Seven Major Market Outlook
14.
Wet AMD Market Drivers
15.
Wet AMD Market Barriers
16.
SWOT Analysis
17.
Wet AMD Market Access
18.
Case Study
19.
KOL Views
20.
Bibliography
21.
Appendix
22.
DelveInsight Capabilities
23.
Disclaimer
24.
About DelveInsight
Get in touch with our business executive for Healthcare Due Diligence Services
Related Reports
Age-related Macular Degeneration (AMD) Market
DelveInsight’s “Age-related Macular Degeneration (AMD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Age-related Macular Degeneration (AMD), historical and forecasted epidemiology as well as the Age-related Macular Degeneration (AMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/